By 2013, over 685,000 PCI and 165,000 CABG procedures will be performed, according to Millennium Research Group

May 14, 2009—Waltham, Massachusetts— According to two new Millennium Research Group (MRG) reports, emerging clinical data and innovations in device technology will shift the balance between percutaneous coronary intervention (PCI) and coronary artery bypass graft (CABG) procedures for unique subgroups with coronary artery disease through 2013. MRG’s European Markets for Interventional Cardiology Devices 2009 and European Markets for Coronary Artery Bypass Graft Devices 2009 reports indicate that by 2013, over 685,000 PCI procedures and over 165,000 CABG procedures will be performed across Europe.

Results of clinical studies supporting the benefits of PCI will expand the eligible patient population to include higher-risk subgroups, which until recently have been untreated by PCI. In 2008, results of the CARDia trial identified similar rates of myocardial infarction, stroke, or death at 12 months in diabetic patients who received either PCI or CABG surgery. Initial results of the SYNTAX trial found the same trend for patients with complicated forms of CAD. Consequently, while CABG surgery will remain the gold standard treatment for complex CAD, some of these patients may now be considered eligible for PCI.

“Results of recent clinical studies demonstrate that PCI can be used to treat patients with significantly more complicated forms of CAD than previously thought possible,” says Anuk Karunaratne, Senior Analyst at MRG. “Innovations in PCI technology—such as improved stent design and intravascular ultrasound (IVUS)—will enable treatment of more complicated cases and will allow PCI use to expand further into CABG territory, although it’s unlikely that referral patterns will shift significantly in the short-term. Nevertheless, continued innovation and clinical data will influence physicians to select PCI as the optimal treatment for some higher-risk patients.”

MRG’s new reports, European Markets for Interventional Cardiology Devices 2009 and European Markets for Coronary Artery Bypass Graft (CABG) Devices 2009 cover France, Germany, Italy and the UK, and also provide data such as usage rates, units per procedure, average selling prices, and growth rates. Detailed market shares are provided across all market segments for key companies, including Abbott Vascular, Boston Scientific, Johnson & Johnson's Cordis, Medtronic, Sorin Group, Terumo Medical, Volcano, and more.